Korean Journal of Clinical Pharmacy

Table. 3.

Table. 3. Table 3

Trends of contraindicated drug use

Study name	Contraindicated drug use trend

	Pre-DUR	Post- DUR	Pre-DUR vs. Post-DUR	Findings

				Absolute Reduction	Relative Reduction	Others
SO Lee et al.19)	n/d	Not decreased	n/d	Alerts^a DDIs: 225,065, Age: 41,730 Acceptance^b DDIs: -7.8, Age: -10.3

SO Kim et al.21)	n/d	n/d	n/d	n/d

DS Kim et al.22)	n/d	n/d	Decreased			Proportion (‰) before 0.2942, after 0.2211

JY Shin et al.23)	n/d	n/d	Decreased	4.54^c (-4.65, -4.44)

BJ Park et al.24)	n/d	n/d	Decreased	-0.27^c (-0.35, -0.19)	-43.84^c (-52.50, -36.32)

JH Yang et al.25)	n/d	Decreased	n/d			CoefficientIntroduction of DUR (CF: 42.1827, LF: 53.7999, OF: 181.3033, AZ: 184.0676, CT: 242.9162, LP: 69.0648, DG: 0.3380, MG: -0.1230, MP: 2.7672)Trend after DUR (CF: 18.6327, LF: 25.4482, OF: 71.7608, AZ: 77.5579, CT: 157.3654, LP: 70.6703, DG: -0.3134, MG: -0.2323, MP: 1.6104)

IM Song et al.26)	n/d	n/d	Decreased	-4.43^c (-4.43, -4.43)	-27.77^c(-27.90, -27.64)

HN Shin et al.27)	n/d	n/d	Decreased	-1.80^c (-1.87, -1.73)	-85.71^c(-102.72, -71.53)

SY Song et al.28)	n/d	n/d	Decreased	-462515

AR, absolute reduction; AZ, azelastine; CT, cetirizine; CF, ciprofloxacin; DDIs, drug-drug interactions; DG, dydrogesterone; n/d, not determined;

LP, loperamide; LF, levofloxacin; MG, methylergoetrine; MP, micronized progesterone; Pre-DUR, pre-period of DUR system; Post-DUR, post-period of DUR system; Pre-DUR vs. Post-DUR, compare between pre and post period of DUR system; OF, ofloxacin; RR, relative reduction.

number of alert cases,

percentage of the acceptance,

percentage (%)

Korean J Clin Pharm 2019;29:9-17 https://doi.org/10.24304/kjcp.2019.29.1.9